PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

N Dey, P De, B Leyland-Jones - Pharmacology & therapeutics, 2017 - Elsevier
Breast cancer (BC) is the most common women cancer and second most common cause of
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

N Dey, P De, B Leyland-Jones - Pharmacology & …, 2017 - pubmed.ncbi.nlm.nih.gov
Breast cancer (BC) is the most common women cancer and second most common cause of
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.

N Dey, P De, B Leyland-Jones - Pharmacology & Therapeutics, 2017 - europepmc.org
Breast cancer (BC) is the most common women cancer and second most common cause of
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …

[引用][C] PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

N Dey, P De, B Leyland-Jones - Pharmacology & Therapeutics, 2017 - cir.nii.ac.jp
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォーム …